Issues in Oncology

Hematologic Malignancies

Logistics of CAR T-Cell Therapy in Real-World Practice

Susan London  / May 25, 2018

With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially curative options for incurable hematologic malignancies. Its ...

Issues in Oncology

Informed Consent and the Oncologist: Legal Duties to Discuss Costs of Treatment

Thaddeus Mason Pope, JD, PhD  / November 25, 2017

For 50 years, clinicians in the United States have had a legal duty to disclose to patients with cancer the risks, benefits, and alternatives to a proposed cancer treatment. Until recently, however, it has been unclear whether clinicians have a similar duty to discuss the costs of tha...

Issues in Oncology
Cost of Care

With Financial Toxicity in Oncology Care on the Rise, Providers Need to Help Address Patients’ Financial Issues

Ronald Piana  / October 10, 2017  / 2017 Quality Care Symposium

At the 2017 ASCO Quality Care Symposium, Dan Sherman, MA, LPC, discussed potential solutions to the persistent challenge of financial toxicity in the oncology setting. Mr. Sherman is a clinical financial consultant and Founder and President of The Navectis Group, Caledonia, Michigan. Rather than foc...

Prostate Cancer
Issues in Oncology

A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?

Ronald Piana  / December 25, 2016

The diagnosis and treatment of prostate cancer have long been a source of controversy among the oncology community, the political sector, and patient advocacy groups. Most notably, the decision to biopsy a man’s prostate gland rests largely on his prostate-specific antigen (PSA) test ...

Issues in Oncology

Friends of Cancer Research Rethinks Traditional Clinical Trials

Margot J. Fromer  / December 10, 2016

Ellen V. Sigal, PhD, Chair and Founder of Friends of Cancer Research (Friends) began the annual meeting with a conversation with Douglas R. Lowy, MD, National Cancer Institute (NCI) Acting Director, and Robert M. Califf, MD, U.S. Food and Drug Administration (FDA) Commissioner. “Cancer researc...

Issues in Oncology
Cost of Care

Understanding Biosimilars and Their Impending Role in Oncology Care

Margot J. Fromer  / November 25, 2016

Biosimilars are among the newest threads in the fabric of cancer treatment in the United States, and they are spawning numerous questions for oncologists and patients with cancer. Many of these questions were taken up by participants in a recent Washington forum on “The Future of the U.S. Biosimilar...

Cost of Care
Issues in Oncology

As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients

Caroline McNeil  / November 10, 2016

The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the ...

Issues in Oncology
Cost of Care

COA Releases 2016 Community Oncology Practice Impact Report

The ASCO Post  / October 25, 2016

On October 4, the Community Oncology Alliance (COA) released the 2016 Community Oncology Practice Impact Report, which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation in...

Issues in Oncology

Breaking the ‘Conspiracy of Silence’

Jo Cavallo  / September 25, 2016

A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of...

Issues in Oncology

The Halifax Project: A New Approach to Combination Therapy

Ronald Piana  / September 25, 2016

On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the o...

Issues in Oncology

Educating People About Clinical Trials May Improve Their Likelihood of Participation

Jo Cavallo  / August 10, 2016

The facts are well known: Although clinical trials are regarded as the gold standard to investigate whether a new treatment is safe and effective in patients—and have resulted in advances in cancer cures and increases in cancer survivorship—only 3% to 5% of patients enroll in these studies.1 The rea...

Colorectal Cancer

Prevention Needed to Stem Global Rise in Human Papillomavirus–Related Anal Cancer

Ronald Piana  / July 10, 2016

The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, is rising in the United States and globally. Although 5-year survival rates in localized disease are generally favorable, survival in metastatic disease remai...

Issues in Oncology

Low-Dose Chemical Exposure and Cancer

Ronald Piana  / June 10, 2016

According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true bu...

Breast Density Legislation: An Opportunity for Better Risk Assessment

Caroline Helwick  / June 10, 2016

Dense breasts are not an automatic indication for additional imaging. Instead, breast density generally provides an opportunity for improved risk assessment, according to Kevin Hughes, MD, of Massachusetts General Hospital, Boston. “More than 20 states have mandated that women be informed of ...

ASCO Updates Value in Cancer Care Framework

The ASCO Post  / June 10, 2016

On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms or...

ASCO Value in Cancer Care Task Force

The ASCO Post  / June 10, 2016

The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs ...

Issues in Oncology

Leading Surgical Oncology Societies Call for Global Curriculum to Address Variations, Inadequacies in Training

The ASCO Post  / May 25, 2016

The lack of an adequately trained workforce of surgical oncologists can be a major detriment in efforts to address the rising global cancer burden, according to two leading international surgical oncology societies. In two jointly published reports,1,2 the Society of Surgical Oncology (SSO) and the...

Issues in Oncology
Global Cancer Care

A Perilous Time for Refugees With Cancer

Jo Cavallo  / May 25, 2016

The numbers are difficult to fathom. According to a report by the United Nations High Commissioner for Refugees (UNHCR), in 2015, over 60 million people worldwide were forcibly displaced as a result of conflict, persecution, generalized violence, or human rights violations.1 Over 9 million of those ...

Issues in Oncology

CancerCare Issues Report on Nationwide Surveys of 3,000 People Diagnosed With Cancer

Jo Cavallo  / May 10, 2016

The national nonprofit organization CancerCare has announced the publication of a comprehensive report on experiences, perceptions, and needs of people who are living with and beyond a cancer diagnosis. The 2016 CancerCare Patient Access and Engagement Report is a compilation of results from si...

Issues in Oncology

Breakthrough Therapy Efforts Result in Unprecedented Success

Margot J. Fromer  / May 10, 2016

Friends of Cancer Research (Friends) and the U.S. Food and Drug Administration (FDA) have been working together for many years on an idea known as breakthrough therapy, and it has produced results beyond anyone’s hopes. Said Ellen Sigal, PhD, Friends Chair and Founder, “When we were first talki...

ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer

The ASCO Post  / April 25, 2016

Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,1 the statemen...

Issues in Oncology

Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored

Margot J. Fromer  / April 25, 2016

Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical tria...

Issues in Oncology

Friends of Cancer Research Encourages FDA to Modernize and Consolidate

Margot J. Fromer  / April 25, 2016

“In order to take advantage of today’s advancements in science, drug development, and patient treatment, the U.S. Food and Drug Administration’s (FDA’s) structure needs reorganization to focus its resources and ensure the best outcomes for patients. Friends of Cancer Research (Friends) proposes enha...

Gastroesophageal Cancer

Survival Period for Esophageal Cancer Is Tied to Race and Income

The ASCO Post  / April 10, 2016

African American patients with esophageal cancer survive fewer months after diagnosis than white patients, but only if they also have low incomes, according to a study presented by Loretta ­Erhunmwunsee, MD, at the Annual Meeting of the Society of Thoracic Surgeons. Dr. ­Erhunmwunsee led the study w...

Issues in Oncology

Somebody’s Watching You: Meet the Tweet Trackers of the Social Oncology Project

Kirsten Boyd Goldberg  / March 25, 2016

In a one-story concrete industrial building across the street from a lumberyard in Austin, Texas, Greg Matthews and his computers are tracking everything that more than 500,000 U.S.-based physicians post publicly on social media. Every tweet. Every public blog, Facebook, or Instagram post. Ever...

Issues in Oncology

Quality Improvement Projects Aim at Reducing Errors in Prescribing IV and Oral Chemotherapy

Charlotte Bath  / March 25, 2016

Two quality improvement projects described in the Journal of Oncology Practice resulted in reduced errors in prescribing intravenous (IV) and oral chemotherapy. A project at the University of Texas Medical Branch in Galveston outpatient infusion centers first identified 15 different types of deviat...

Issues in Oncology

ASCO Provides Support and Guidance for the White House Cancer Moonshot Initiative

Jo Cavallo  / March 10, 2016

Although President Richard Nixon signed the National Cancer Act in 1971, essentially declaring a war on cancer, the genesis of the idea had actually been born 2 years earlier, after the first landing on the moon set off a new era of scientific exploration and sparked a belief that any scientific ach...

Issues in Oncology

ASCO Issues Policy Statement Calling for Improvements to Clinical Pathway Programs in Oncology

The ASCO Post  / February 10, 2016

ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice,1 the statement asserted that the way in which these treatment management tools in ca...

Palliative Care

Perceptions of End-of-Life Care Differ Sharply Between African Americans and White Americans

Ronald Piana  / December 25, 2015

Studies demonstrate that patients with advanced cancer who are not actively engaged in planning their end-of-life care often receive overly aggressive, physically taxing, costly and unnecessary treatment toward life’s end. Recent findings indicate that African Americans appear to be more apt to requ...

Issues in Oncology

Debate Over Physician-Assisted Suicide Continues, State by State

Ronald Piana  / November 10, 2015

In 1997, after surviving a storm of high-court legal challenges, Oregon’s Death With Dignity Act went into effect, making Oregon the first American state to legalize physician-assisted suicide. The Supreme Court ruled that there was no right to assisted suicide in the Constitution but implied that s...

ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality

The ASCO Post  / November 10, 2015

ASCO recently called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve “site neutrality” in reimb...

Issues in Oncology

Maternal Cancer During Pregnancy Does Not Appear to Affect Cognitive or General Development in Early Childhood

Matthew Stenger  / October 25, 2015

In a study reported in The New England Journal of Medicine, Frederic Amant, MD, PhD, of University Hospitals Leuven, Belgium, and colleagues in the International Network on Cancer, Infertility, and Pregnancy found that cancer diagnosed during pregnancy did not appear to affect cognitive, cardiac, or...

Cost of Care

Making Their Voices Heard: 118 Oncologists Speak Out About Stemming the High Cost of Cancer Drugs

Jo Cavallo  / September 25, 2015

In a bold move to shed light on the ramifications of the ever-increasing cost of cancer drugs for patients with cancer and for the health-care system, 118 prominent oncologists came together to write a commentary in Mayo Clinic Proceedings detailing their concerns.1 To learn more about these proposa...

Health-Care Policy

‘Right to Try’ Laws: Helpful or Harmful?

Jo Cavallo  / August 25, 2015

Since 2014, “Right to Try” legislation has been sweeping the nation. Created to enable terminally ill patients to gain access to experimental drugs, biologics, and devices by sidestepping the approval process of the U.S. Food and Drug Administration (FDA), at press time, 22 states have enacted Right...

Cost of Care

Calculating the Value of Cancer Drugs

Jo Cavallo  / August 25, 2015

For nearly a decade, Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, has been a leading voice in sounding the alarm over the escalating cost of cancer drugs and in seeking a solution to the problem. In 2012, Dr. Ba...

Issues in Oncology

Johnson & Johnson Creates Independent Bioethics Panel to Evaluate Compassionate Drug Use Requests

Jo Cavallo  / August 25, 2015

In May 2015, Johnson & Johnson announced its partnership with New York University (NYU) School of Medicine in New York to create a first-of-its kind independent bioethics panel to review requests made to the company for compassionate use of an investigational drug and determine how the company s...

Issues in Oncology

Is Proton-Beam Therapy Facing a Difficult Future?

Ronald Piana  / August 10, 2015

Health-care experts are questioning whether proton-beam therapy is on the verge of an economic bubble—ie, a rapid surge in growth for the industry beyond its intrinsic value, inevitably leading to a drastic drop in earnings for proton centers when the “bubble bursts.” A proton-beam facility can cost...

Cost of Care

ESMO’s Magnitude of Clinical Benefit Scale Brings Unbiased Perspective to Cancer Drugs’ Worth

Caroline Helwick  / August 10, 2015  / 2015 ASCO Annual Meeting

An anticancer therapy may be hailed as a breakthrough in some corners, whereas its value may be hotly contested in others. In an effort to bring clear, unbiased perspective to new expensive therapies, the European Society for Medical Oncology (ESMO) has created a valuable tool for oncologists, patie...

Cost of Care

The Value Proposition in Oncology: ASCO Session Weighs Points of View

Chase Doyle  / August 10, 2015  / 2015 ASCO Annual Meeting

The value proposition in health care is often represented with the following equation: Value = Outcomes/Cost. The simplicity of this equation, however, belies the complexity of its parts, which are the contributions of multiple stakeholders with unique perspectives. A session presented at the 2015 ...

Cost of Care
Hematologic Malignancies

Study Shows Current Blood Cancer Drug Prices Are Not Justified

The ASCO Post  / August 10, 2015

The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic cancers are currently...

Issues in Oncology

American College of Physicians Releases High Value Care Screening Advice for Five Common Cancers

The ASCO Post  / August 10, 2015

In a paper published in Annals of Internal Medicine1, the American College of Physicians (ACP) issued advice for screening average risk adults without symptoms for five common cancers: breast, colorectal, ovarian, prostate, and cervical. In a companion piece also published in Annals2, ACP outlined a...

Health-Care Policy

Medicare to Reimburse Doctors for End-of-Life Counseling

Ronald Piana  / August 10, 2015

In a breakthrough proposal announced on July 8, the Centers for Medicare & Medicaid Services (CMS) plans to reimburse physicians for end-of-life counseling, a move that the oncology community has long been lobbying for. Arriving just as the presidential election cycle begins to heat up, the CMS ...

Breast Cancer

First National Data on Breast Cancer Subtypes Mark New Era in Biomarker Epidemiology

Caroline McNeil  / June 10, 2015

This year’s Report to the Nation on the Status of Cancer contains the first national combined data set on the incidence of four major breast cancer subtypes by race/ethnicity, poverty level, geography, and other factors. The findings show that “there are unique racial/ethnic-specific incidence patte...

Cost of Care

Cancer Survivors Face Lasting Financial Struggles Long After Treatment Ends, New Study Reports

The ASCO Post  / October 15, 2014

The majority (62%) of America’s middle-income cancer survivors say they were not financially prepared for cancer diagnosis and treatment, according to a new study released by the Washington National Institute for Wellness Solutions (IWS). The study, “Insights from Survivors: Managing the Personal, ...

Delivering Affordable Cancer Care: Is It Possible and What Will It Entail?

Margot J. Fromer  / November 15, 2012

Many experts agree that at 18% of gross domestic product, health care (to paraphrase Shakespeare) is eating the country out of house and home. “The average cost of treating the most common cancers has increased, and as more expensive targeted therapies and other new technologies become the standard...

Lung Cancer
Issues in Oncology

After a Decade of Decline in Smoking Rates, Progress Has Stalled

Margot J. Fromer  / July 15, 2012

Approximately 20% of all Americans smoke, and 443,000 of them will die each year as a result. Tobacco use is the leading cause of preventable death in the United States and the greatest behavioral determinant of morbidity and mortality (6%–10% of U.S. health-care costs). Nearly 30% of all cancer dea...

Issues in Oncology
Health-Care Policy

Oncology Drug Shortage: An Unintended Consequence of the Medicare Modernization Act and Free-market Forces?

Ronald Piana  / September 15, 2011

Oncology has a drug shortage problem, and the FDA says that it is getting worse. Drug shortages are not a new phenomenon, but over the past few years we have seen a rapidly growing number of shortfalls that are limiting providers’ ability to care for their patients. In 2004, the FDA reported 58 drug...

Issues in Oncology

Research in Combining Targeted Agents Faces Numerous Challenges

Margot J. Fromer  / September 1, 2011

If the clinical trials endeavor in oncology is falling short of its goals and if targeted agents have not kept their promise, can a new approach to drug development provide a solution? Very possibly, said John Hohneker, MD, Chair of the Workshop Planning Committee for the conference, “Facilitating ...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.